We are live on ! Find out more
IPHA

Innate Pharma
IPHA

18 hedge funds and large institutions have $5.82M invested in Innate Pharma in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,866% more capital invested

Capital invested by funds: $296K → $5.82M (+$5.52M)

260% more funds holding

Funds holding: 5 → 18 (+13)

1.08% more ownership

Funds ownership: 0.11% → 1.19% (+1.1%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
18
Holders Change
+13
Holders Change %
+260%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$808K
2
Bank of America
Bank of America
North Carolina
+$750K
3
AAA
Affinity Asset Advisors
New York
+$539K
4
VF
Virtu Financial
New York
+$472K
5
Optiver Holding
Optiver Holding
Netherlands
+$450K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$84.7K
2
Morgan Stanley
Morgan Stanley
New York
-$81.4K
3
SPIA
Steward Partners Investment Advisory
New York
-$646

IPHA Hedge Fund Activity: Q3 2021 in Review

18 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2021, worth a combined $5.82M — up 1,866% from $296K a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IPHA positions and 0 closed out — a net gain of 13 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $808K. The largest seller was Millennium Management, cutting an estimated $84.7K.

  • 18 institutional investors held Innate Pharma (IPHA) as of Q3 2021, up from 5 in Q2 2021.
  • Funds reported $5.82M of Innate Pharma stock for Q3 2021, up 1,866% quarter-over-quarter.
  • 13 funds opened new Innate Pharma positions in Q3 2021 and 0 closed out, a net change of +13 holders.
  • The largest Innate Pharma buyer in Q3 2021 was Balyasny Asset Management, an estimated $808K added.
  • The largest Innate Pharma seller in Q3 2021 was Millennium Management, an estimated $84.7K sold.

Based on aggregated 13F filings for Q3 2021.